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ABSTRACT: 
 
Cystic Fibrosis (CF) is a genetic disorder caused by loss-of-function mutations to the gene encoding the 
cystic fibrosis transmembrane conductance regulator (CFTR) protein. Ivacaftor (1) was the first 
therapeutic approved for the treatment of CF that is able to restore gating activity to certain CFTR variants 
although the mechanism of action is poorly understood. Herein we describe the synthesis of a photoaffinity 
labelling (PAL) probe (2) based on the structure of ivacaftor incorporating a photoreactive diazirine moiety 
for use in labelling studies designed to identify the binding site for ivacaftor on mutant CFTR. The PAL 
probe 2 retained potentiation activity, with a potency similar to 1, using a Fluorescent Imaging Plate 
Reader (FLIPR®) assay measuring ion conductance potentiation of wild type (Wt)-CFTR. Photolabelling 
experiments with human serum albumin (HSA) as a model protein have shown that probe 2 can label HSA 
in a manner consistent with observed and predicted binding.  
 
Graphical Abstract: 
 
 
 
1. Introduction 
 
Cystic fibrosis (CF) is an autosomal recessive disorder and the most common fatal genetic disease 
affecting North Americans.1,2 The underlying cause of CF results from loss-of-function mutations in the 
gene encoding the cystic fibrosis transmembrane conductance regulator protein (CFTR).3–5 Wild-type 
CFTR is a phosphorylation dependent nucleotide regulated ion channel primarily responsible for the flux 
of chloride and bicarbonate across the apical membranes of epithelial tissues.6 For individuals with CF, 
loss of CFTR activity results in dysregulation of ion flux and extracellular fluid composition.7 CF affects 
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many organs in the body including the pancreas, gastrointestinal tract, reproductive system, liver, skin, and 
lungs. Loss of CFTR function in the lungs, the organ most overtly affected, leads to dehydration of the 
airway surface fluid causing mucus plugging, a propensity for bacterial infection, inflammation, 
bronchiectasis and eventually respiratory failure.  
Historically, disease management for CF primarily focused on treating the resulting symptoms including 
the use of antibiotics to combat chronic respiratory infections, aerosolised mucolytics to reduce mucus 
plugging and enzyme administration to aid in digestion and nutrient uptake.8 With the recent development 
and clinical implementation of CFTR modulating small-molecule therapies, clinicians are now able to treat 
the underlying cause of the disease.9 Many classes of CFTR modulators have been described and have 
undergone clinical testing. The first FDA approved CFTR modulator, ivacaftor (1), is termed a CFTR 
“potentiator” as it restores gating to CFTR protein which has been successfully trafficked to the cell 
membrane. Ivacaftor was discovered through the use of high-throughput functional screening followed by 
an extensive medicinal chemistry program.10 As a result, the exact mechanism of action is not yet fully 
understood, including the location of the binding site(s) on mutant CFTR. Understanding the interactions 
between 1 and mutant CFTR will provide insights useful in the development of new therapeutically useful 
compounds. 
One method for identifying the location of the binding site of a compound on its target protein is through 
the use of a photo-affinity labelling (PAL) probe.11 Generating a PAL probe involves the incorporation of a 
photoreactive group onto the compound of interest, which upon irradiation forms a highly reactive species 
that can covalently bind to proximal amino acid residues in the binding site. An important aspect of 
generating a PAL probe is to ensure that incorporation of the reactive moiety does not significantly alter 
the affinity of the probe for the target protein relative to the parent compound. The most common 
photoreactive groups used in PAL probes are the diazirine,12 azide,13 and benzophenone moieties.14,15 Each 
of these groups have different properties, including activation wavelength, nature and half-life of reactive 
species produced, reagent stability, size, lipophilicity, and propensity to rearrange. Additionally, PAL 
probes commonly feature a reporter tag to aid in the identification and isolation of labelled proteins, 
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including secondary targets for the compound of interest.11 A variety of reporter tags can be utilized; such 
as radiolabels, fluorophores, biotin; or a latent group (such as an acetylene) that can be reacted with a 
tagging molecule via click chemistry following the photolabelling event. In recent years the diazirine has 
become a favoured choice of photoreactive group as it is stable to a wide range of reaction conditions, 
activated by a wavelength of light which does not significantly affect proteins or DNA (365 nm) and 
produces a very reactive singlet carbene which has a short half-life and can insert into N-H, C-H, and O-H 
bonds.16,17  
Towards the goal of elucidating the binding site of 1 on mutant CFTR, we have synthesized PAL probe 2, 
featuring a diazirine moiety, based on the ivacaftor scaffold. Herein, we discuss the design and synthesis of 
2, as well as initial characterization of its stability, photoreactivity, and functional activity on the CFTR 
channel. We have demonstrated the ability of 2 to efficiently label human serum albumin (HSA), a protein 
that has been previously reported to have a strong affinity for 1.18 
 
2. Results and discussion 
2.1. Retrosynthetic analysis 
In generating PAL probe 2, it was important to ensure that the installation of the photoreactive group 
would not significantly alter the binding affinity and bioactivity compared to ivacaftor. It has been shown 
that modifications to either of the two t-butyl groups on the scaffold could be tolerated with retention of 
CFTR potentiating activity.10 Modification of the t-butyl group ortho to the phenolic moiety affected the 
potentiation EC50 to a greater degree than did changes to the para-t-butyl, suggesting that the ortho group 
might have a closer interaction with the surface of the binding site on CFTR.10 Considering the similar size 
and lipophilicity of a diazirine moiety compared to a t-butyl group, we envisaged a target PAL probe 
where a diazirine motif replaces the t-butyl group ortho to the phenolic moiety, and thus the molecule 2 
was chosen as our target PAL probe. 
Retrosynthetic analysis of compound 2 suggested two possible synthetic routes (Figure 1). The first 
involved forming an amide bond between carboxylic acid A (potentially substituted with a reporter tag), 
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and an aniline B containing the diazirine moiety. B could be prepared from D where the diazirine group 
would be installed via manipulation of a synthetic handle such as X = Br or I. The second route reversed 
this process, forming the amide bond between aniline D and acid A to give compound C, followed by 
installation of the diazirine group (Figure 1).  
 
 
Figure 1. Retrosynthetic analysis of routes of synthesis of the diazirine-containing PAL probe (R indicates 
potential attachment of a reporter tag) 
 
2.2. Synthesis of PAL probe 2  
Initial synthetic efforts focused on the first route and synthesis of B (compound 3). The synthesis of 3 
(Scheme 1) began from known phenol 4 with the reaction with chloromethyl ethyl ether to give 5.19 
Selective reduction of the nitro group in 5 proceeded smoothly with iron and ammonium chloride to give 
aniline 6, and subsequent protection of the aniline with di-t-butyl dicarbonate (Boc2O) gave 7. Installation 
of the trifluoromethyl ketone was achieved by first deprotonation of the amide NH with MeLi, followed by 
lithium-halogen exchange using n-BuLi, and quenching the resulting di-anion with ethyl trifluoroacetate to 
provide trifluoromethyl ketone 8 in excellent yield (95%). Compound 8 was reacted with hydroxylamine 
hydrochloride in a 2:1 pyridine/methanol mixture to give a mixture of E,Z isomers of oxime 9 in a 2:1 ratio 
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(stereochemistry undetermined). Reaction of oximes 9 with p-toluenesulphonyl chloride gave tosyl-oximes 
10 which were subsequently treated with liquid ammonia in a sealed vessel to give diaziridine 11. Upon 
close inspection, the crude reaction mixture was found to be a 2.7:1 mixture of an amidine by-product 12 
and the desired diaziridine 11. Separation of 12 and isolation of pure 11 could be performed at this stage 
by either semi-preparative HPLC or selective crystallization, but this was somewhat demanding and low 
yielding. The identity of this side product 12 was unambiguously confirmed by single crystal X-ray 
diffraction (Scheme 1, Supplementary Information Figure S1). A better overall yield of the final product 
(the diazirine 13) and easier separation was achieved by carrying the mixture of 11 and 12 into the next 
step. Oxidation of the mixture of 11 and 12 with iodine and trimethylamine in methanol smoothly gave 13 
(along with unchanged amidine 12), which was easily obtained pure via silica chromatography (shielded 
from light). The deprotection of 13 with methanolic hydrogen chloride produced the desired aniline 3; 
however, this species was found to be very reactive with a short half-life, quickly forming adducts with 
solvent. Nonetheless, with 3 in hand, amide coupling reactions with 4-oxo-1,4-dihydroquinoline-3-
carboxylic acid (14) were attempted under a variety of conditions, but all attempts resulted in loss of the 
diazirine and production of products of decomposition of the diazirine. Unfortunately, despite extreme 
precautions to exclude light, the aniline 3 proved to be too unstable to survive the relatively slow amide 
bond forming reactions with 14 and thus this approach was abandoned. 
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Scheme 1. Synthesis of diazirine 3a 
 
aReagents and conditions: (i) Chloromethyl ethyl ether, DIPEA, THF, rt; (ii) Fe, NH4Cl, MeOH, 60 oC; 
(iii) Boc2O, Toluene, 105 oC, Microwave; (iv) a) MeLi, THF, -40 oC to rt, b) n-BuLi, THF, -78 oC, c) ethyl 
trifluoroacetate, -78 oC to rt; (v) HONH3·Cl, 2:1 pyridine/MeOH, 65 oC, 18 h; (vi) TsCl, DIPEA, DCM, 0 
oC to rt; (vii) NH3 (l), DCM, 18 h, -78 oC to rt; (viii) I2, Et3N, MeOH, 18 h; (ix) HCl (g) MeOH.  
 
Although we were unable to couple 3 with 14 with retention of the diazirine, we wanted to confirm that the 
photolytic decomposition of the diazirine group in the protected precursor 13 proceeded as expected. Thus, 
a solution of diazirine 13 in methanol was irradiated with UV light (365 nm) and the methanol photo-
adduct 15 was isolated in excellent yield (Scheme 2). Notably, while 3 was very unstable, 13 was found to 
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be much less sensitive to light and we therefore surmised that installation of the diazirine after amide 
formation would have a greater chance of success. 
Scheme 2. Photoreaction of diazirine 13 with MeOH 
 
 
We therefore turned our attention to the alternative synthetic route (Figure 1, path B) where the two halves 
of the molecule were coupled at an early stage and the diazirine installed later as shown in Scheme 3. 
Coupling of aniline 6 and acid 14 with HATU gave bromo-amide 16 in good yield on multi-gram scale. 
Lithium-halogen exchange of the bromine atom in 16 was achieved by first addition of 2 equiv of MeLi to 
remove the NH protons followed by treatment with n-BuLi to generate a tri-anion species, which upon 
reaction with ethyl trifluoroacetate produced trifluoromethyl ketone 17. Trifluoromethyl ketone 17 was 
isolated as a mixture of ketone and hydrate or hemi-ketal forms. At this stage, pure ketone 17 could be 
isolated by preparative-scale high-pressure liquid chromatography (prep-HPLC) in the absence of 
alcoholic solvents but only in low yields. However, carrying the original mixture forward directly into 
reaction with hydroxylamine hydrochloride gave the oximes 18 in better overall yield. In this way 18 could 
be isolated in 53% yield for the two steps as a mixture of E/Z isomers (2:1 ratio, undefined) by 
precipitation from DCM and without need for chromatography.  Conversion of oximes 18 to the 
corresponding tosylate and formation of diaziridine 19 was carried out as a two-step, one-pot procedure. 
After reaction of 18 with p-toluenesulphonyl chloride in DCM, the reaction mixture was transferred to a 
reaction vessel containing condensed liquid ammonia and sealed at -40 oC and then allowed to react while 
warming to room temperature to give a mixture of diaziridine 19 and amidine 20 in a 2.6:1 ratio. Pure 
diaziridine 19 was successfully isolated by preparative reverse-phase HPLC. Diaziridine oxidation 
proceeded smoothly with Dess-Martin periodinane (DMP) to give diazirine 21, and final deprotection with 
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methanolic HCl gave our target diazirine 2. Gratifyingly, 2 did not require further purification and was 
stable for up to a year when stored cold (-20 oC) in the dark as either a solid or as a solution in DMSO. 
 
Scheme 3. Synthesis of PAL probe 2a 
 
aReagents and conditions: (i) HATU, HOBt, DIPEA, DMAP, DMF, 60 oC, 18h; (ii) a) MeLi, THF, -40 oC; 
b) n-BuLi, THF, -78 oC; c) ethyl trifluoroacetate, -78 oC to rt; (iii) HONH2·HCl, 2:1 pyridine/MeOH, 60 
oC, 18 h; (iv) a) TsCl, DIPEA, DCM, 0 oC to rt; b) NH3 (l), DCM, 18 h, -40 oC to rt; (v) Dess-Martin 
periodinane, DCM, 2 h; (vi) HCl (g), MeOH.  
 
A solution of diazirine 2 in methanol was irradiated with UV light (365 nm) (Scheme 4) and monitored by 
HPLC and LC-MS which after 3 hours showed essentially complete conversion to the methanol adduct 22. 
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Scheme 4. Photoreaction of 2 with MeOH 
 
 
2.3. Protein labelling and biological evaluation of photoaffinity probe 2 
To develop conditions for labelling proteins with probe 2, photolabelling experiments were performed with 
a readily available model protein, human serum albumin (HSA). Recombinant HSA (Sigma, Cat# A7736, 
Lot# SLBN1719V) was chosen for these experiments as ivacaftor has been reported to bind strongly to 
HSA in vitro (KD = 15.3 ± 11.2 µM) and molecular modeling studies predicted two putative binding 
sites.18 Solutions containing various concentrations and ratios of 2 and HSA were irradiated with 365 nm 
centered light for 30 minutes and the extent of labelling was determined by LC-MS looking for protein 
adducts with m/z indicative of covalent labelling of HSA (Figure 2 and Supplemental Information, Figure 
S2). Two major deconvoluted mass signals were observed for unlabelled HSA, m/z 66321 (Peak A) and 
m/z 66440 (Peak B). Following UV irradiation of HSA in the presence of one molar equivalent of 2, two 
new major peaks were observed at m/z 66737 (Peak C) and m/z 66856 (Peak D) corresponding to a shift of 
the two major HSA mass peaks by 416 amu, the mass shift predicted for monolabelling by 2. Peaks 
corresponding to doubly labelled HSA (M+832) were also observed in one experiment, but to a much 
lesser extent and were not included in calculation of the extent of labelling. Based on the ratio of measured 
peak abundances of the mass-shifted signals to the residual unlabelled HSA peaks (Supplementary 
Information, Table S2) we could calculate the percentage labelling (Figure 2) using the general formula:  
 
% labelling =  ________Peak A + Peak B                  X 100%  
                          Peak A + Peak B + Peak C + Peak D   
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After 30 minutes of exposure to UV light of a 1:1 mixture of 2 and HSA (1.5 µM in 3% DMSO in water), 
the extent of labelled protein was determined to be 37% (Figure 2 and Supplemental Information). 
Examination of the extracted ion count (EIC) after 30 min of irradiation showed a significant amount of 
unreacted 2 remaining (data not shown). In order to ensure that labelling was via a UV-mediated process, a 
1:1 solution of HSA and probe 2 was kept in the dark and monitored by LC-MS and showed a background 
labelling rate of 7% after 30 min, which is significantly lower than that obtained with overt UV exposure. 
Competitive inhibition of the labelling of HSA by 2 with ivacaftor was evaluated to determine if the 
labelling events occurred in a manner specific for a putative ivacaftor binding site(s) on HSA. Addition of 
150 µM ivacaftor to the solution of 1:1 mixture of 2 and HSA (both 1.5 µM in 3% DMSO in water) 
significantly reduced the extent of labelling by 2 (from 37% to 15%; p < 0.0001, Figure 2). No significant 
difference found in labelling after addition of 10 equiv (15 µM) of 1. However, significant inhibition of 
labelling was observed when ivacaftor (15 M) was first allowed to equilibrate with HSA for 30 minutes 
prior to addition of 2 and then irradiation (Figure S3). Photolabelling was not completely inhibited by 
ivacaftor under either condition indicating that at least some portion of the labelling of HSA by 2 was non-
specific which is not surprizing given the micromolar binding affinity of ivacaftor for HSA (vide supra) 
(and by inference also of 2) and the multiple potential binding sites available on HSA.   
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Figure 2. Photolabelling of HSA (1.5 µM in 3% DMSO in water) with 2 (1.5 µM) following 30 min of 
irradiation with 365 nm light, and reduction in photolabelling in presence of 10 and 100 equiv of 
1 (15 M and 150 µM respectively). Significance refers to difference from HSA + 2 + UV. *** 
p<0.001, two-tailed t-test, calculated with GraphPad Prism.  
  
To further identify the site(s) of modification of HSA by 2, we used tandem MS/MS and shotgun 
proteomics approach to identify the labelled peptides by Sequest (an automatic peptide sequencing 
algorithm)20 through Discoverer 2.1 software (Thermo-Fisher Scientific). A solution of HSA, after 
photolabelling with 2, was subjected to enzymatic digestion with trypsin (Trypsin Gold, Promega, Cat. 
No.: V5280) and the resulting peptides were analyzed on an Orbitrap Q Exactive HF (Thermo-Fisher 
Scientific) coupled with EASY-NLC 1000 nanoHPLC (Thermo-Fisher Scientific). In total, 7 HSA labelled 
peptides were identified and are tabulated in the Supplemental Information (Table S4 and Figures S4-
S10). The most abundantly observed labelled peptide (P1: [R].YTKKVPQVSTPTLVEVSR.[N], Uniprot# 
P02768 [437-454]21,22) borders the known multi-drug binding site on subdomain IIIA,22,23 that was 
predicted by Schneider et al18 as a binding site for 1 on HSA. The location of this peptide is highlighted in 
red and purple on the HSA crystal structure24 in Figure 3. The exact site of modification on each modified 
peptide was difficult to determine as the label was lost during the MS/MS fragmentation process 
(appearance of MH+; 417.14 Da signal, Supplemental Information Figures S4-10). 
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Figure 3. A) Peptides labelled by 2 identified by MS/MS on the HSA ribbon structure: P1, red (and 
purple); P2 (overlaps with P1), purple; P3, blue; P4, cyan; P5, orange; P6, pink; P7 yellow. 
(Graphic generated in PyMol; PDB ID: 1AO624; Uniprot Assn No. P0276821). B) Probe 2 
(magenta) modelled, using Genetic Optimization for Ligand Docking (GOLD) version 5.5, in 
the multi-drug binding site on subdomain IIIA in a manner and orientation as described for 
ivacaftor by Schneider et al18. 
 
In order to determine whether installation of the diazirine moiety onto the ivacaftor scaffold was 
deleterious to bioactivity, the ability of the probes to potentiate Wt-CFTR in HEK cells was determined 
using a FLIPR® membrane potential assay, where changes in fluorescence are a readout of CFTR channel 
activity 25,26. A representative FLIPR® trace is shown in Figure 4A. The response of the CFTR channel to 
activation by forskolin (leading to membrane depolarization) is enhanced by the addition of ivacaftor (1) 
or probe 2. As expected, the response to forskolin in the presence of both compounds was inhibited by the 
specific CFTR inhibitor: CFTRinh-172.27 Analysis of the dose responses for each probe revealed that 
addition of the diazirine moiety shifted the EC50 for ivacaftor from 0.20 µM to 0.56 µM (Figure 4B) but 
did not significantly affect its efficacy. These results suggest that probe 2 is able to access the putative 
ivacaftor binding site on CFTR in a manner similar to 1. 
A B 
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Figure 4. A) Representative trace from the FLIPR® assay comparing potentiation of Wt-CFTR in HEK 
cells. First arrowhead indicates the addition of 1 µM forskolin in combination with either 
DMSO, 10 µM ivacaftor (1), or 10 µM probe 2. Second arrowhead indicates the addition of 
10µM CFTR-inh172. Data was normalized to the last point of the baseline read (RFU: relative 
fluorescence units). B) Dose response curves of ivacaftor (1) and probe 2 (n=3-4). ΔFmax values 
were determined by subtracting ΔRFUFSK (changes in fluorescence from forskolin addition 
alone) from ΔRFUFSK+probe (changes in fluorescence from forskolin addition in the presence of 
varying concentrations of 1 or 2). From the fitted dose response curves, the EC50 values of 1 and 
2 were determined to be 0.20 µM and 0.56 µM, respectively.  
 
 
3. Conclusions  
 
A photoaffinity labelling probe 2, based on the structure of ivacaftor and featuring a diazirine moiety in 
place of one of the t-butyl groups has been synthesized. The photoreactive properties of the diazirine 
moiety were confirmed by irradiating 2 in methanol at 365 nm to generate the methanol adduct 22. As 
well, photolabelling experiments with a model protein (HSA) have shown that 2 is able to label protein 
efficiently and in a specific manner that can be outcompeted by ivacaftor. Potent and comparable 
potentiation of ion channel activity of CFTR by 2 comparable to ivacaftor has been confirmed through the 
use of a fluorescence-based FLIPR assay with Wt-CFTR. This probe should be useful to identify the 
putative binding site(s) of ivacaftor on the CFTR ion channel. 
 
4. Experimental 
 
4.1. General Chemistry 
 
THF was distilled from Na and benzophenone under N2. N,N’-diisopropylethylamine (DIPEA) and 
triethylamine (Et3N) were distilled from CaH2 and stored under N2. All other reagents and solvents were 
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used as received from commercial suppliers unless otherwise stated. Analytical thin-layer chromatography 
(TLC) was performed on aluminum plates pre-coated with silica gel 60F-254 as the absorbent, and eluted 
with the solvent systems indicated, visualization of the plates was done with UV light (254 nm) and the 
indicated stains. Melting point was measured on a Fisher-Johns melting point apparatus and are 
uncorrected. Microwave reactions were conducted in a Biotage Initiator. 
Flash chromatography was performed with a Biotage Isolera One system using SiliCycle SiliaSepTM 
Cartridges of indicated size and solvent gradient. 1H, 19F and 13C NMR spectra were recorded with Bruker 
Avance II™ 600 MHz, Bruker Avance III™ 500 MHz, or Bruker Avance III™ 400 MHz. 1H and 13C 
NMR spectra were referenced to the various solvent signals28 and processing of the spectra was performed 
with MestRecNova™ software (Note: numbering of atoms for the purposes of signal assignment did not 
follow IUPAC numbering schemes). The high-resolution mass spectra were recorded with an ESI ion 
source on an Agilent™ Time-of-Flight LC/MS mass spectrometer (Model 6210) using a Halo C18 
(2.1x50mm) water-ACN (5mM NH4OAc) gradient. All HPLC analyses were performed utilizing an 
Advanced Materials Technologies Halo™ C18 reverse-phase analytical column (4.6 × 50 mm, 5 μm) with 
a water-ACN (5mM NH4OAc) gradient. All preparative HPLC purifications were carried out using a 
Phenomenex Kinetex C18 reverse-phase preparatory column (21.2 × 150 mm, 5 μm) with a water-ACN 
(5mM NH4OAc) gradient. UV-Vis spectra were collected in solution phase in a quartz cuvette on a Varian 
Cary 5000 UV-Vis-NIR Spectrophotometer. ATR spectra were collected with a Perkin Elmer Spectrum 
Two™ FT-IR spectrometer, and absorption bands were designated as weak (w), broad (br), medium (m), 
or strong (s). Photo-decomposition studies were performed (when indicated) in a light-box composed of 
two Dreamall 36W UV Acrylic Curing Light Lamps taped together each with 4 x 9W UV bulbs emitting at 
365 nm or with a UVP Mineralight© lamp (115 V, 60 Hz, 0.16 A) and irradiated at 365 nm (long UV 
wavelength setting).  
For Single-Crystal X-ray diffraction structure determinations, single crystals were selected and mounted 
using Paratone oil on a 150 μm MiTeGen Dual-Thickness MicroMount. Data was collected at room 
temperature with a Bruker SMART APEX II Duo CCD diffractometer using a TRIUMPH graphite-
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monochromated Cu-Kα radiation (λ = 1.54184 Å). Crystallographic information for 12 can be found in 
Supplemental Information (Table S1, Figure S1). All diffraction data were processed with the Bruker 
Apex II software suite. Initial solutions were obtained by using the intrinsic phasing method29 with 
subsequent refinements performed with SHELXL30 on the SHELXLE platform.31 Diagrams were prepared 
by using ORTEP-332 and POV-RAY.33 
 
4.2. 1-Bromo-5-(tert-butyl)-2-(ethoxymethoxy)-4-nitrobenzene (5) 
To a solution of 2-bromo-4-(tert-butyl)-5-nitrophenol (4) (prepared according to DeMattei et al.)19 (9.9 g, 
36 mmol) in THF (60 mL) at room temperature under N2, DIPEA (19 mL, 109 mmol) was added, followed 
by chloromethyl ethyl ether (5.3 mL, 58 mmol) and stirred overnight. The reaction mixture was quenched 
with sat. aq. NH4Cl (100 mL), and extracted with Et2O (50 mL, 3x). The organic layers were combined, 
washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness to give compound 5 
(10.7 g, 32 mmol, 89%) as a yellow crystalline solid. 1H NMR (600 MHz, CDCl3) δ 7.69 (s, 1H), 7.17 (s, 
1H), 5.28 (s, 2H), 3.76 (q, J = 7.1 Hz, 2H), 1.37 (s, 9H), 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) δ 152.4, 150.5, 135.8, 133.3, 115.3, 111.4, 94.3, 77.2, 65.2, 35.3, 30.8, 15.1. mp = 62 - 63 oC.  
 
4.3. 4-Bromo-2-(tert-butyl)-5-(ethoxymethoxy)aniline (6) 
To a solution of 1-bromo-5-(tert-butyl)-2-(ethoxymethoxy)-4-nitrobenzene (5) (502 mg, 1.51 mmol) 
dissolved in MeOH (15 mL), Fe powder (2 g, 36 mmol, 24 equiv), and NH4Cl (1.5 g, 28 mmol, 18 equiv) 
were added and the reaction was heated at 60oC for 4 hours. The crude mixture was allowed to cool and 
then filtered through a bed of Celite, washed with MeOH, and the filtrate was concentrated to dryness. The 
crude residue was purified by automated flash chromatography on a 25 g silica cartridge (20% EtOAc/Hex 
isocratic elution) to give compound 6 (345 mg, 1.14 mmol, 76% yield) as a yellow oil. 1H NMR (CDCl3, 
400 MHz) δ 7.30 (1H, s), 6.52 (1H, s), 5.22 (2H, s), 3.77 (2H, q, J=7.1 Hz), 1.38 (9H, s), 1.24 (3H, t, J=7.1 
Hz). 13C NMR (101 MHz, CDCl3) δ 152.7, 145.1, 131.1, 129.3, 105.6, 100.7, 94.0, 77.2, 64.7, 34.0, 29.8, 
15.2. HRMS: m/z calcd for C13H20BrNO2: 302.0750 (M+H); found 302.0781.  
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4.4. tert-Butyl (4-bromo-2-(tert-butyl)-5-(ethoxymethoxy)phenyl)carbamate (7) 
A solution of aniline 6 (2.6 g, 8.6 mmol) dissolved in toluene (5 mL) was placed in a microwave vial and 
then degassed under argon. Boc2O (7.5 g, 34.4 mmol, 4 equiv) was added under argon, the microwave vial 
was sealed and the reaction mixture was heated in the microwave reactor for 18 h at 105 oC. The reaction 
mixture was cooled to room temperature and the vial was vented by puncturing the septa with a large bore 
needle. The crude mixture was concentrated to dryness, and the residue was purified by column 
chromatography on an 80 g silica cartridge (2-20 % EtOAc/Hex gradient) to give 7 (2.49 g, 6.2 mmol, 72 
%) as a white crystalline solid. Remaining unreacted 6 (369 mg, 1.2 mmol, 14%) was recovered and 
recycled. 1H NMR (500 MHz, CDCl3) δ 7.48 (s, 1H), 7.46 (s, 1H), 6.35 (s, 1H), 5.28 (s, 2H), 3.79 (q, J = 
7.1 Hz, 2H), 1.50 (s, 9H), 1.37 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 153.2, 
152.2, 136.2, 130.9, 114.0, 108.3, 94.0, 80.8, 77.2, 64.9, 34.2, 30.8, 28.5, 15.2. HRMS: m/z calcd for 
C18H28BrNO4: 402.1274 (M+H); found 402.1271. mp = 94 - 95 oC.  
 
4.5. tert-Butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoroacetyl)phenyl)carbamate (8) 
A solution of 7 (526 mg, 1.31 mmol) in THF (5 mL) under N2 was cooled to -40 oC. MeLi (1.75 mL, 2.6 
mmol, 2 equiv) was added via syringe and the reaction mixture was warmed to 0 oC for 2 minutes. The 
reaction mixture was cooled to -78 oC and n-BuLi (1.30 mL, 1.96 mmol, 1.5 equiv) was added dropwise 
via syringe and the reaction mixture was stirred for 1 h. Ethyl trifluoroacetate (2.0 mL, 17 mmol, 13 equiv) 
was added quickly via syringe and the reaction mixture was warmed to room temperature. The reaction 
was quenched with sat. aq. NH4Cl (10 mL), extracted into EtOAc (50 mL), then washed with brine (30 
mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude residue was purified via 
automated flash chromatography on a 25 g silica cartridge (2-30% EtOAc/Hex), to afford compound 8 
(520 mg, 1.24 mmol, 95 % yield) as a white crystalline solid. 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 
7.72 (s, 1H), 6.88 (s, 1H), 5.32 (s, 2H), 3.77 (q, J = 7.1 Hz, 2H), 1.54 (s, 9H), 1.42 (s, 9H), 1.24 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 181.3 (q, J = 36.1 Hz), 157.4, 152.0, 144.0, 131.1, 130.2, 116.7 
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(q, J = 290.8 Hz), 116.4, 107.9, 93.6, 81.8, 65.1, 33.9, 30.7, 28.4, 15.1. 19F NMR (376 MHz, CDCl3) δ -
73.68. HRMS: m/z calcd for C20H28F3NO5: 420.1992 (M+H); found 420.2003. mp = 89.5 - 90.5 oC.  
 
4.6. tert-butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoro-1-
(hydroxyimino)ethyl)phenyl)carbamate (9) 
A solution of compound 8 (110 mg, 0.262 mmol) and hydroxylamine hydrochloride (22 mg, 0.315 mmol) 
in a 2:1 mixture of pyridine/MeOH (7.5 mL) was stirred at 60 oC overnight. The reaction mixture was 
cooled to room temperature and concentrated to dryness. The crude residue was purified via automated 
flash chromatography (12 g silica cartridge, 4-40 % EtOAc/Hex gradient) to afford compound 9 (90 mg, 
207 mmol, 79 % yield) as a mixture of E/Z isomers, as a white crystalline solid. 1H NMR (400 MHz, 
CDCl3) δ 8.08 (s, 1H), 7.72 (s, 1H), 7.69 (s, 1H), 7.63 (s, 2H), 7.18 (s, 2H), 7.11 (s, 1H), 6.56 (s, 2H), 5.24 
(s, 4H), 5.23 (s, 2H), 3.72 (q, J = 7.1, 6H), 3.71 (q, J = 7.2 Hz, 6H),1.52 (s, 11H), 1.52 (s, 16H), 1.39 (s, 
11H), 1.39 (s, 16H), 1.22 (td, J = 7.1, 2.1 Hz, 9H). 13C NMR (151 MHz, CDCl3) δ 154.8, 153.6, 147.6 (q, J 
= 32.0 Hz), 146.6 (q, J = 33.6 Hz), 139.1, 128.7, 127.1, 120.7 (q, J = 274.4 Hz), 118.2 (q, J = 282.3 Hz), 
116.3, 112.3, 111.3, 93.5, 93.4, 81.3, 64.7, 64.6, 34.1, 34.0, 30.8, 30.7, 28.5, 15.1. 19F NMR (376 MHz, 
CDCl3) δ -65.2, -67.5. HRMS: m/z calcd for C20H29F3N2O5: 433.1956 (M-H); found 433.2044. mp = 149 - 
157 °C.  
 
4.7. tert-butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoro-1-
((tosyloxy)imino)ethyl)phenyl)carbamate (10) 
Et3N (170 μL, 1.22 mmol, 1.5 equiv) was added to a solution of 9 (353 mg, 0.81 mmol) in DCM (10 mL) 
at 0 oC, via syringe and after stirring for 5 minutes, p-TsCl (170 mg, 0.89 mmol, 1.1 equiv.) was added and 
the reaction mixture was stirred for 15 minutes while warming to room temperature. The mixture was then 
quenched with sat. aq. NH4Cl (3 mL), washed with brine (3 mL), and dried (Na2SO4) to give tosyl oxime 
10 as a crude yellow oil (495 mg) which was used directly in the subsequent step. 1H NMR (400 MHz, 
CDCl3) δ 7.9-7.85 (m, 7H), 7.76 (s, 1H), 7.69 (s, 2H), 7.38-7.35 (m, 7H), 7.02 (s, 1H), 6.90 (s, 2H), 6.61 
(s, 1H), 6.60 (s, 2H), 5.15 (s, 4H), 5.13 (s, 2H), 3.63 (q, J=7.1 Hz, 4H), 3.62 (q, J=7.0 Hz, 2H), 2.48 (s, 
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3H), 2.46 (s, 6H), 1.53 (s, 9H), 1.51 (s, 18H), 1.38 (s, 9H), 1.34 (s, 18H), 1.19 (t, J = 7.1, 3H), 1.18 (t, J = 
7.1, 6H). 19F NMR (376 MHz, CDCl3) δ -64.5, -67.6. HRMS: m/z calcd for C27H35F3N2O7S: 606.2455 
(M+NH4+); found 606.2508. 
Alternatively, the reaction mixture could be used directly, before quenching and without workup, in the 
subsequent reaction to give diaziridine 11.  
 
4.8. tert-butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)diaziridin-3-yl)phenyl)carbamate 
(11) and tert-butyl (Z)-(4-((1-amino-2,2,2-trifluoroethylidene)amino)-2-(tert-butyl)-5-
(ethoxymethoxy)phenyl)carbamate (12) 
Ammonia was condensed (~1.5 mL) at -78 oC into a sealable reaction vessel, and a portion of the reaction 
mixture of tosyl-oxime 10 from above (theoretical mass of 118 mg, 0.2 mmol) in DCM (3 mL) was 
transferred via pipette into the liquid ammonia. The reaction vessel was sealed and the reaction mixture 
was warmed to room temperature in a water bath and stirred overnight. The reaction vessel was cooled at -
78 oC for 15 minutes then carefully opened, and the reaction mixture was warmed at room temperature for 
30 minutes. The reaction mixture was concentrated to dryness and the residue was purified by column 
chromatography on a 25 g silica cartridge (4-40 % EtOAc/Hex) to afford a mixture of diaziridine 11 and 
amidine 12 in a 1:2.7 ratio by 1H NMR. The mixture of diaziridine 11 and amidine 12 can then be utilized 
directly in the next step (oxidation to diazirine 13) and separation of the diazirine 13 and amidine 12 post-
oxidation can be performed by automated flash chromatography. 
For characterization purposes a mixture of 11 and 12 (80 mg, 1:2 ratio) was separated via preparative 
reverse phase HPLC to give 11 as a white crystalline solid (16 mg), and 12 as a white crystalline solid (20 
mg). 12 was then recrystallized from an 8:2 Et2O/Hex mixture and the structure of 12 was confirmed by X-
ray crystallography (performed by CMH with instruction and assistance from JT).  
 
4.8.1. Characterization data for 11 
 1H NMR (500 MHz, CDCl3) δ 7.59 (s, 1H, C-6-H), 7.41 (s, 1H, C-3-H), 6.53 (s, 1H, N-H), 5.35 – 5.18 
(m, 2H, C-9-H), 3.78 – 3.70 (m, 2H, C-10-H), 2.65 (d, J = 9.0 Hz, 1H, diaziridine-N-H), 2.49 (d, J = 8.7 
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Hz, 1H, diaziridine-N-H), 1.51 (s, 9H, C-8-H), 1.39 (s, 9H, C-14-H), 1.24 (t, J = 7.1 Hz, 3H, C-11-H). 13C 
NMR (126 MHz, CDCl3) δ 154.9 (C-5), 153.0 (C-12), 138.9 (C-1), 133.3 (C-2), 128.9 (C-3), 123.7 (q, 1JC-
F = 278.8 Hz, C-16), 115.8 (C-4), 110.7 (C-6), 93.3 (C-9), 81.0 (C-5), 64.8 (C-10), 56.2 (q, 2JC-F = 37.1 Hz, 
C-15), 34.0 (C-7), 30.8 (C-8), 28.5 (C-14), 15.2 (C-11). 19F NMR (471 MHz, CDCl3) δ -77.0. HRMS: m/z 
calcd for C20H30F3N3O4: 472.1825 (M+K); found 472.1837. mp = 127-128 oC. 
 
4.8.2. Characterization data for 12. 1 
H NMR (400 MHz, CDCl3) δ 7.29 (s, 1H, C-6-H), 6.89 (s, 1H, C-3-H), 6.28 (s, 1H, N-H), 5.10 (s, 2H, C-
9-H), 5.07 (s, 2H, amidine-N-H), 3.67 (q, J = 7.1 Hz, 2H, C-10-H), 1.48 (s, 9H, C-14-H), 1.34 (s, 9H, C-8-
H), 1.18 (t, J = 7.1 Hz, 3H, C-11-H). 13C NMR (101 MHz, CDCl3) δ 153.9 (C-12), 145.3 (C-5), 145.3 (q, 
2JC-F = 35.2 Hz, C-17), 137.7 (C-2), 133.0 (C-4), 132.7 (C-1), 121.3 (C-3), 118.3 (q, 1JC-F = 277.9 Hz, C-
18), 116.6 (C-6), 94.5 (C-9), 80.4 (C-13), 64.6 (C-10), 34.3 (C-7), 30.8 (C-8), 28.5 (C-14), 15.0 (C-11). 19F 
NMR (376 MHz, CDCl3) δ -72.80. HRMS: m/z calcd for C20H30F3N3O4: 434.2261 (M+H); found 
434.2249. mp = 124 - 126 °C. IR (cm-1) 3427 (w), 3288 (w), 3186 (w), 2981-2896 (m), 1700 (s), 1682 (s), 
1625 (w), 1483 (s),1139 (s). 
 
4.9. tert-Butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)carbamate (13) 
The mixture from above containing diaziridine 11 and amidine 12 (222 mg, 11:12 in ratio of 1:1.6, total 
0.5 mmol) (calculated 11, 0.2 mmol) was dissolved in MeOH (3 mL) and Et3N (180 μl, 1.28 mmol, 2.5 
equiv) was added and the reaction mixture was stirred for 5 minutes. I2 (71 mg, 0.56 mmol, 1.1 equiv) was 
added and the reaction mixture was stirred overnight and monitored by TLC. The reaction mixture was 
quenched with Na2S2O3 (aq.) and extracted into EtOAc (30 mL). The organic fractions were combined and 
washed with sat. aq. NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, and concentrated to dryness. 
The crude residue was purified by automated flash chromatography on a 12 g silica cartridge (4-40% 
EtOAc/Hex gradient) to give compound 13 (63 mg, 0.15 mmol, 18%  yield over 3 steps) as a white 
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crystalline solid. 1H NMR (400 MHz, CD3OD) δ 7.46 (s, 1H, C-3-H), 7.16 (s, 1H, C-6-H), 5.34 (s, 2H, C-
9-H), 3.78 (q, J = 7.1 Hz, 2H, C-10-H), 1.50 (s, 9H, C-14-H), 1.37 (s, 9H, C-8-H), 1.22 (t, J = 7.1 Hz, 3H, 
C-11-H). 13C NMR (151 MHz, CD3OD) δ 157.3 (C-5), 156.6 (C-12), 140.9 (C-2), 140.7 (C-4), 129.7 (C-
3), 123.6 (q, 1J C-F = 273.9 Hz, C-16), 117.8 (C-6), 115.6 (C-1), 94.4 (C-9), 81.5 (C-13), 65.7 (C-10), 35.5 
(C-7), 31.1 (C-8), 28.7 (C-14), 27.6 (q, 2J C-F = 42.4 Hz, C-15), 15.4 (C-11). 19F NMR (376 MHz, CD3OD) 
δ -70.7. HRMS: m/z calcd for C20H28F3N3O4: 449.2370 (M+NH4+); found 449.2365.  
 
4.10. tert-Butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoro-1-methoxyethyl)phenyl)carbamate 
(15) 
A solution of diazirine 13 (3 mg, 7 μmol) dissolved in MeOH (300 μL) was placed in an NMR tube, which 
was suspended in a UV light-box comprised of two Dreamall UV lamps (described above) and irradiated 
for 48h. The reaction mixture was concentrated to dryness to give the methanol adduct 15 as a white solid 
(3 mg, 6.9 μmol, quantitative yield). 1H NMR (600 MHz, MeOD) δ 7.50 (s, 1H), 7.10 (s, 1H), 5.29 – 5.23 
(m, 2H), 5.14 (q, 3JH-F = 6.7 Hz, 1H), 3.72 (q, J = 7.1 Hz, 2H), 3.35 (s, 3H), 1.51 (s, 9H), 1.38 (s, 9H), 1.21 
(t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, MeOD) δ 157.0, 155.7, 140.8, 138.7, 127.5, 125.5 (q, 1JC-F= 
281.2 Hz), 120.4, 117.5, 94.5, 81.2, 75.3 (q, 2JC-F = 31.9 Hz), 65.5, 58.3, 35.6, 31.3, 28.8, 15.4. 19F NMR 
(376 MHz, CD3OD) δ -78.2. HRMS: m/z calcd for C21H32F3NO5: 453.2571 [M+NH4]+; found 453.2577. 
mp = 71 – 73 °C 
 
4.11. 5-Amino-4-(tert-butyl)-2-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenol (3) 
To a solution of compound 13 (62 mg, 0.144 mmol) dissolved in MeOH (1 mL), sat. methanolic HCl (1 
mL, prepared by bubbling HCl (g) through methanol) was added and the reaction mixture was stirred for 1 
hour, monitored by TLC and LC-MS. The reaction mixture was blown dry under a stream of nitrogen to 
give compound 3 (34 mg, 0.124 mmol, 86 % yield) as the HCl salt as a crystalline solid which was used 
immediately in subsequent reactions. 1H NMR (500 MHz, CD3OD) δ 7.29 (s, 1H), 6.44 (s, 1H), 1.38 (s, 
9H). 19F NMR (471 MHz, CD3OD) δ -70.68. HRMS: m/z calcd for C12H14F3N3O: 274.1162 (M+H); found 
274.1142.  
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4.12. N-(4-bromo-2-(tert-butyl)-5-(ethoxymethoxy)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
(16) 
A mixture of aniline 6 (2.00 g, 6.62 mmol), HATU (5.03 g, 6.62 mmol, 2 equiv), 1,4-dihydro-4-
oxoquinoline-3-carboxylic acid (14) (1.88 g, 9.93 mmol, 1.5 equiv), DMAP (81 mg, 0.66 mmol, 0.1 
equiv), and HOBt (895 mg, 6.62 mmol, 1 equiv) were dissolved in DMF (20 mL). DIPEA (3.5 mL, 19.9 
mmol, 3 equiv.) was added and the reaction mixture was stirred overnight at 60 oC. The reaction mixture 
was cooled to room temperature and concentrated to remove DMF. The crude residue was diluted with 
EtOAc (200 mL) and washed with sat. aq. NaHCO3 (100 mL), brine (50 mL), dried over Na2SO4, and 
concentrated to dryness. The crude residue was purified by automated flash chromatography on an 80 g 
silica cartridge (75-100% EtOAc/Hex) to give amide 16 as a white crystalline solid (2.6 g, 5.5 mmol, 83 % 
yield). 1H NMR (500 MHz, CDCl3) δ 12.60 (s, 1H), 12.52 (d, J = 6.4 Hz, 1H), 9.08 (d, J = 6.8 Hz, 1H), 
8.43 (dd, J = 1.8, 7.8 Hz, 1H), 7.77 (s, 1H), 7.48 – 7.40 (m, 2H), 7.34 (s, 1H), 6.02 (dd, J = 1.2, 7.4 Hz, 
1H), 5.08 (s, 2H), 3.48 (q, J = 7.1 Hz, 2H), 1.45 (s, 9H), 0.97 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 177.9, 165.8, 152.5, 144.4, 141.4, 139.2, 135.5, 133.1, 131.7, 126.6, 126.1, 125.6, 118.6, 117.9, 
111.0, 110.3, 93.8, 77.2, 64.8, 34.8, 30.8, 14.9. HRMS: m/z calcd for C23H25BrN2O4: 473.1071 (M+H); 
found 473.1051. mp = 205 - 206.5 oC.  
 
4.13. N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoroacetyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-
carboxamide (17) 
A solution of compound 16 (230 mg, 0.486 mmol) in THF (10 mL) under N2 was cooled at -40 oC and 
MeLi (1.6 M, 700 μL, 1.12 mmol, 2.3 equiv) was added via syringe and the reaction mixture was stirred 
for 2 min. At -40 oC, n-BuLi (1.58 M, 370 μL, 0.583 mmol, 1.5 equiv) was added dropwise via syringe and 
the reaction mixture was stirred a further 15 minutes. Ethyl trifluoroacetate (1.7 mL, 15 mmol, 30 equiv) 
was added quickly via syringe and the reaction mixture was warmed to 0 oC then quenched with saturated 
aqueous NH4Cl (1 mL). The reaction mixture was extracted into EtOAc (5 mL) and the organic fractions 
were combined and washed with brine (2 mL) dried over Na2SO4 and concentrated to dryness to give 
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crude compound 17 as a yellow oil (270 mg). This crude material was utilized without purification in the 
subsequent oxime formation reaction. 
For characterization purposes a portion of crude residue was purified by preparative reverse phase HPLC 
then lyophilized to give 17 (11 mg, 0.022 mmol, 53% yield from 0.042 mmol of 16) as a white crystalline 
solid. The chromatogram from preparative HPLC at 254 nm showed conversion to 17 of approximately 65 
% and based on this value the product was approximately 0.32 mmol in the crude mixture. 
1H NMR (600 MHz, CDCl3) δ 12.66 (s, 1H), 11.63 (s, 1H), 9.01 (s, 1H), 8.49 – 8.42 (m, 1H), 7.91 (s, 1H), 
7.78 (s, 1H,), 7.44 (m, 2H), 6.65 (d, J = 7.4 Hz, 1H), 5.19 (s, 2H), 3.59 (q, J = 7.1 Hz, 2H), 1.52 (s, 9H), 
1.08 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 182.4 (q, 2J C-F = 36.0 Hz), 177.7, 165.2, 156.2, 
144.4, 142.8, 139.0, 137.9, 133.2, 130.4, 126.7, 126.6, 125.9, 119.4, 118.2, 116.5 (q, 1J C-F = 290.7 Hz), 
114.8, 110.7, 93.4, 65.2, 34.8, 30.5, 15.0. HRMS: m/z calcd for C25H26F3N2O5: 491.1788 (M+H); found 
491.1741 m/z. mp = 107 – 109 °C.  
 
4.14. N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoro-1-(hydroxyimino)ethyl)phenyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide (18) 
Hydroxylamine hydrochloride (42 mg, 0.61 mmol, ~1.9 equiv) was added to the crude residue containing 
compound 17 obtained in the previous reaction (270 mg, ~0.32 mmol) in a 2:1 mixture of pyridine/MeOH, 
and the reaction mixture was heated overnight at 60 oC. The crude reaction mixture was cooled to room 
temperature, concentrated to dryness, and the residue was purified by automated flash chromatography on 
a 12 g silica column (30-100% EtOAc/Hex gradient). The purified product was recrystallized from a 
1:10:2 MeOH/DCM/Hexanes mixture to give compound 18 (285 mg, 0.56 mmol, 53% yield over two 
steps) as a white solid (>95% pure by HPLC). 1H NMR (400 MHz, CD3OD) δ 8.90 (s, 1H), 8.43 (dd, J = 
1.4, 8.3 Hz, 1H), 7.82 (ddd, J = 1.5, 7.1, 8.5 Hz, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.60 – 7.51 (m, 3H), 7.31 
(s, 1H), 7.22 (s, 1H), 5.26 (s, 2H), 5.24 (s, 2H), 3.72 (q, J = 7.1 Hz, 2H), 3.72 (q, J = 7.1 Hz, 2H), 1.48 (s, 
9H), 1.47 (s, 9H), 1.20 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 178.8, 
166.1, 166.0, 155.7, 154.5, 146.6, 145.7, 140.8, 138.9, 138.7, 138.2, 138.2, 134.4, 130.0, 128.5, 127.7, 
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127.0, 126.8, 124.0, 122.5, 121.2, 120.0, 120.0, 118.4, 116.4, 116.1, 116.1, 115.8, 115.8, 112.0, 101.4, 
94.7, 94.4, 65.5, 49.0, 35.2, 31.0, 15.4. 19F NMR (376 MHz, CD3OD) δ -66.5, -68.5..HRMS: m/z calcd for 
C25H26F3N3O5: 506.1897 (M+H); found 506.1920. mp = 207 - 210 oC.  
 
4.15. N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)diaziridin-3-yl)phenyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide (19) and (Z)-N-(4-((1-amino-2,2,2-trifluoroethylidene)amino)-2-
(tert-butyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (20) 
DIPEA (133 μL, 0.75 mmol, 3 equiv) was added to a solution of oxime 18 (126 mg, 0.250 mmol) in DCM, 
and stirred until all solids dissolved; then the reaction mixture was cooled to 0 oC and p-TsCl (62 mg, 1.3 
equiv) was added. The reaction mixture was stirred for 15 minutes, then warmed to room temperature, and 
stirred for 15 minutes. The progress of the reaction was monitored by LC-MS. The crude reaction mixture 
was added directly to a sealable vessel containing NH3 (l) at -40 oC. The reaction mixture was sealed in the 
vessel and stirred overnight at room temperature. The reaction mixture was cooled to -60 oC and stirred for 
15 minutes, then the reaction vessel was opened, and the reaction mixture was allowed to warm to room 
temperature and stirred for 15 minutes. The reaction mixture was purified by preparative-scale HPLC, 
(55% ACN/H2O, 5mM NH4OAc isocratic elution) and lyophilized to give diaziridine 19 (44 mg, 0.087 
mmol, 35% over 2 steps), and amidine 20 (20 mg, 0.040 mmol, 13 % from 18) as white amorphous solids. 
 
4.15.1. Characterization data for 19  
1H NMR (601 MHz, CDCl3) δ 12.51 (s, 1H), 11.97 (s, 1H), 9.05 (d, J = 4.5 Hz, 1H), 8.45 (dd, J = 1.5, 8.1 
Hz, 1H), 7.70 (s, 1H), 7.51 – 7.45 (m, 2H), 7.44 – 7.39 (m, 1H), 6.35 (d, J = 8.2 Hz, 1H), 5.11 (s, 2H), 3.59 
– 3.45 (m, 2H), 2.72 (d, J = 9.0 Hz, 1H, diaziridine-N-H), 2.32 (d, J = 9.0 Hz, 1H, diaziridine-N-H), 1.50 
(s, 9H), 1.04 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 177.7, 165.4, 154.6, 144.4, 139.1, 138.5, 
138.1, 132.9, 129.7, 126.7, 126.5, 125.6, 123.6 (q, 1JC-F = 279.1 Hz), 118.3, 118.3, 115.1, 110.7, 93.1, 64.8, 
56.3 (q, 2JC-F = 37.0 Hz), 34.7, 30.8, 15.0. 19F NMR (471 MHz, CDCl3) δ -76.86. HRMS: m/z calcd for 
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C25H27F3N4O4: 505.2057 (M+H); found 505.2085. mp = 145 - 147 oC. IR (cm-1): 3235 (w), 2959 (w), 1644 
(m), 1568 (m), 1520 (s), 1476 (s), 1148 (s).  
 
4.15.2. Characterization data for 20.  
1H NMR (400 MHz, Acetone-d6) δ 11.94 (s, 1H), 8.96 (s, 1H), 8.44 (ddd, J = 0.7, 1.4, 8.1 Hz, 1H), 7.95 – 
7.71 (m, 2H), 7.60 (s, 1H), 7.54 (ddd, J = 1.7, 6.4, 8.2 Hz, 1H), 6.91 (s, 1H), 6.47 (s, 2H), 5.16 (s, 2H), 
3.72 (q, J = 7.1 Hz, 2H), 1.46 (s, 9H), 1.16 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, Acetone-d6) δ 177.0, 
177.0, 163.0, 162.9, 145.5, 145.4 (q, J = 34.1 Hz), 145.3 (q, J = 34.2 Hz), 144.1, 139.4, 137.2, 137.2, 
133.8, 132.8, 132.2, 132.1, 126.7, 126.7, 126.0, 125.0, 125.0, 120.2, 118.9 (q, J = 278.6 Hz), 118.8, 117.1, 
117.0, 111.9, 111.9, 93.9, 63.9, 34.0, 30.0, 30.0, 14.5. 19F NMR (376 MHz, Acetone-d6) δ -73.1, -73.1. 
HRMS: m/z calcd for C25H27F3N4O4: 505.2057 (M+H); found 505.1870. 
 
4.16. N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide (21) 
DMP (38 mg, 0.090 mmol, 3.0 equiv.) was added to a solution of diaziridine 19 (15 mg, 0.030 mmol) in 
DCM (300 μL) in an amber vial wrapped in foil and the reaction mixture was stirred for 1 hour. The 
reaction mixture was quenched with 1M aqueous NaOH (2 mL), and the organic layer was washed with 
H2O (2 mL), brine (1 mL) and dried over Na2SO4, filtered, and blown dry under a stream of N2 then dried 
under vacuum to give 21 (11 mg, 0.022 mmol, 74% yield) as a white powder (>95% pure by 1H NMR and 
LC-MS). 1H NMR (600 MHz, CDCl3) δ 12.57 (s, 1H), 12.08 (s, 1H), 9.04 (d, J = 4.9 Hz, 1H), 8.44 (dd, J = 
1.5, 8.1 Hz, 1H), 7.64 (s, 1H), 7.48 (s, 1H), 7.42 (ddd, J = 1.1, 7.0, 8.1 Hz, 1H), 7.30 – 7.25 (m, 1H), 6.30 
(d, J = 8.3 Hz, 1H), 5.15 (s, 2H), 3.56 (q, J = 7.1 Hz, 2H), 1.48 (s, 9H), 1.03 (t, J = 7.1 Hz, 3H). 13C NMR 
(151 MHz, CDCl3) δ 177.7, 165.5, 155.9, 144.3, 139.2, 139.1, 138.8, 133.0, 129.2, 126.6, 126.4, 125.6, 
122.2 (q, 1JC-F = 274.9 Hz), 118.1, 115.6, 115.0, 110.5, 93.0, 64.8, 34.7, 30.7, 26.6 (q, 2JC-F = 42.6 Hz), 
15.0. 19F NMR (376 MHz, CDCl3) δ -68.7. HRMS: m/z calcd for C25H25F3N4O4: 503.1901 (M+H); found 
503.1914.  
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4.17. N-(2-(tert-butyl)-5-hydroxy-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide (2) 
Saturated methanolic HCl (250 μL) was added to a solution of diazirine 21 (11 mg, 0.022 mmol) in MeOH 
(400 μL), in an amber vial wrapped in foil and the reaction mixture was stirred at room temperature for 2 
hours. The progress of the reaction was monitored by LC-MS and TLC (EtOAc). The reaction mixture was 
blown dry under a stream of N2 (g) and then placed under high vacuum to give phenol 2 (10 mg, 0.022 
mmol, quant. yield) as a white solid residue. 1H NMR (600 MHz, CD3OD) δ 8.88 (s, 1H, C-H-19), 8.41 (d, 
J = 8.0 Hz, 1H, C-H-23), 7.82 (t, J = 7.5 Hz, 1H, C-H-25), 7.68 (d, J = 8.1 Hz, 1H, C-H-26), 7.56 (t, J = 
7.4 Hz, 1H, C-H-24), 7.44 (s, 1H, C-H-3), 7.23 (s, 1H, C-H-6), 1.45 (s, 9H, C-H-8). 13C NMR (151 MHz, 
CD3OD) δ 178.7 (C-21), 165.8 (C-28), 157.7 (C-5), 145.6 (C-19), 140.7 (C- 27), 139.4 (C-1), 136.5 (C-2), 
134.5 (C-25), 129.4 (C-3), 127.6 (C-22), 126.9 (C-23), 126.8 (C-24), 123.8 (q, J = 273.9 Hz, C-16), 120.0 
(C-26), 117.1 (C-6), 112.5 (C-4), 111.8 (C-23), 35.1 (C-7), 30.9 (C-8), 27.6 (q, J = 42.5 Hz, C-15). 19F 
NMR (376 MHz, CD3OD) δ -70.54. HRMS: m/z calcd for C22H19F3N4O3: 445.1487 (M+H); found 
445.1474. UV (MeOH) λmax 311 nm.  
 
4.18. N-(2-(tert-butyl)-5-hydroxy-4-(2,2,2-trifluoro-1-methoxyethyl)phenyl)-4-oxo-1,4-dihydroquinoline-
3-carboxamide (22) 
A solution of diazirine 2 (7 mg, 0.016 mmol) in MeOH (1 mL), in a clear vial was placed on its side onto 
an upturned UVP Mineralight© lamp (115 V, 60 Hz, 0.16 A) and irradiated at 365 nm (long UV 
wavelength setting). The progress of the reaction was monitored by HPLC and LC-MS. After 3 hours of 
irradiation the majority of the starting material was converted to a new species with mass corresponding to 
the methanol adduct, the reaction mixture was then blown dry under nitrogen. A pure sample of 22 was 
obtained by silica chromatography (75-100 % EtOAc/Hex); compound 22 (1 mg). 1H NMR (400 MHz, 
CD3OD) δ 8.90 (s, 1H), 8.43 (dd, J = 1.2, 8.1 Hz, 1H), 7.82 (ddd, J = 1.5, 7.0, 8.4 Hz, 1H), 7.68 (d, J = 8.0 
Hz, 1H), 7.56 (ddd, J = 1.1, 7.0, 8.2 Hz, 1H), 7.49 (s, 1H), 7.13 (s, 1H), 5.16 (q, J = 6.9 Hz, 1H), 3.38 (s, 
3H), 1.45 (s, 9H). 13C NMR (151 MHz, CD3OD) δ 178.8, 166.0, 155.8, 145.6, 140.8, 137.6, 136.6, 134.4, 
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127.7, 127.3, 126.9, 126.8, 125.8 (q, J = 280.2, 280.7 Hz), 120.0, 117.5, 116.7, 112.1, 75.4 (q, J = 31.4 
Hz), 58.1, 35.2, 31.2. 19F NMR (376 MHz, CD3OD) δ -78.1. HRMS: m/z calcd for C23H23F3N2O4: 
449.1683 (M+H); found 449.1683. 
 
4.19. FLiPR membrane potential assay: 
 
The FLiPR membrane potential assay was conducted as previously described by Molinski et al.34 
HEK cells expressing Wt-CFTR were grown in black 96 well Costar plates with clear bottoms at 37°C 
with 5% CO2. When the cells reached 100% confluency, they were loaded with blue membrane potential 
dye (Molecular ProbesTM) at 0.5 mg/mL dissolved in a buffer containing 136 mM sodium gluconate, 3 mM 
potassium gluconate, 10 mM glucose and 20 mM HEPES (pH 7.35, 300mOsm). After a 45 minute 
incubation time at 37 °C, the plate fluorescence was read with a SpectraMax i3x plate reader (Molecular 
Devices) with the excitation and emission wavelengths set at 530nm and 560nm, respectively.  
The baseline was first read for five minutes. Forskolin (Sigma), VX-770 or its analog were added 
subsequently to stimulate CFTR channel activity for 10 minutes; CFTR inhibitor 172 (Cystic Fibrosis 
Foundation Therapeutics) was added at the end of the assay to inhibit CFTR channel activity for 10 
minutes. 
Statistical analysis was performed using GraphPad Prism v6.01. 
 
4.20. Photolabelling of HSA: 
 
Lyophilized recombinant human serum albumin (HSA) (Lot # SLBN1719V) was purchased from Sigma-
Aldrich. A stock solution of 30 µM HSA was prepared by dissolving 2 mg HSA in 1mL of milliQ 
deionized water, and then filtering through a 0.45 µm syringe filter. A 2.25 mM in DMSO stock solution 
of probe 2 was prepared by dissolving 1 mg of 2 in 1 mL of DMSO and was stored at -20 oC wrapped in 
foil. Similarly, 2.25 mM and 22.5 mM stock solutions of ivacaftor were also prepared in DMSO. Solutions 
of 1.5 μM HSA, 1.5 μM 2, and 0, 10, and 100 uM ivacaftor (1) in 3% DMSO in 1 mL water were prepared 
in HPLC vials. Each solution was prepared by adding the stock probe 2 solution and varying amounts of 
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the stock ivacaftor solutions to a clear conical HPLC vial, diluting the mixture up to 30 µL in DMSO and 
then adding 920 µL of milliQ water before sealing the vials. 50 µL of HSA stock solution was then added 
through the septa via syringe and the solution was vortexed for 5 seconds. The samples were then analyzed 
by LC-MS to obtain zero time reading. Following t = 0 time-point, each vial (except for dark controls 
which were kept wrapped in foil) was placed on a UVP Mineralight© lamp (115 V, 60 Hz, 0.16 A) and 
irradiated at 365 nm (long UV wavelength setting) for 30 minutes and then analyzed by LC-MS. 
Deconvolution of the TIC signal was performed in MassHunterTM to obtain the mass spectrum for HSA. 
The peak lists for each HSA mass spectrum time point were exported to a spreadsheet (Supplemental 
Information Table S2). The percent labelling value was calculated from the ratio of peak abundances of 
the major labelled and unlabelled HSA peaks at t = 30 min using the following formula (Section 2.3): 
% labelling =  ________Peak A + Peak B                  X 100%  
                          Peak A + Peak B + Peak C + Peak D   
 
4.21. Trypsin digestion of labelled HSA and proteomics analysis: 
 
A 1 mL 3% DMSO solution of 2 (1.5 nmol) and lyophilized human serum albumin (HSA, 1.5 nmol) was 
prepared and irradiated as above for 30 minutes and then concentrated to dryness on a Thermo Scientific 
Savant SpeedVac® Concentrator (SPD131DDA) before being reconstituted in 36.5 µL 40 mM Tris at pH 
8.0, 10 µL 50 mM EDTA, 10 µL 0.1 M TCEP, 2.5 µL 20% SDS, and heated at 100 oC for 10 min. Urea 
powder of 48 mg was then added and the solution was incubated at 37 oC for 30 min with agitation on a 
shaker plate. Subsequently, 1.4 µL 0.5 M iodoacetamide (IAA) was introduced and the solution was 
incubated in the dark for 30 min at room temperature. Excessive IAA was quenched by 2.8 µL 1 M 
dithiothreitol (DTT) at room temperature for 15 min. The sample solution was diluted to 1 mL with 20 
mM Tris at pH 8.0 prior to the addition of 5 µg of trypsin (Trypsin gold, Promega, Cat. No. V5280) to 
affect proteolysis at 37 oC for 16 h with agitation on a shaker plate. The digested peptide solution was then 
acidified to pH ~ 3 with 1 M HCl and loaded onto an Oasis ® MCX 1cc cartridge (Waters Co., Lot No. 
013037086A) for desalting. The eluted peptides were dried on the SpeedVac®. 
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4.21.1. Mass Spectrometry analysis of HSA peptide fragments:  
 
The purified peptides were dissolved in 40 µL of 0.1% formic acid and analyzed on a Q Exactive HF 
Orbitrap® mass spectrometer (Thermo Scientific, Mississauga, ON, Canada) coupled with an EASY nLC 
1000® (Thermo Scientific) UHPLC through the nano-EASY spray source (Thermo Scientific) for the 
analyses. The separation was carried out using commercial Pepmap EASY-spray® C18 trap and analytical 
columns (Thermo Fisher) of 75 μm ID, 3 μm C18 resin with 100 Å pore size at 20 and 150 mm length 
respectively for a 20 min gradient of 2−35% buffer B (0.1% FA in acetonitrile), as detailed previously 
(Sun et al. JPR, 2017).35 A voltage of 2.0 kV was used for electrospray, and the ion transfer tube that 
guided ions from spray into MS had a temperature of 250  C̊.  
For Q-Exactive HF MS/MS analysis, data-dependent method was used to select top 5 most abundant 
precursor ions in MS 1 scan for high collision dissociation (HCD) MS/MS fragmentation with a dynamic 
exclusion of 10 sec. The MS1 precursor scan was acquired at m/z range of 400-2000 with mass resolution 
of 60,000 and the MS2 resolution is 15, 000. The automatic gain control (AGC) value for MS1 and MS2 
scans is of 1E6 and 1E3, respectively. Precursors with changes of >5, and the unassigned were excluded 
from MS2 scans. 
 
4.21.2. MS/MS data analysis: 
The resolved raw files from Q-Exactive HF® were processed by Proteome Discoverer 2.1® (Thermo 
Scientific, Mississauga, ON, Canada) and searched using Sequest HT®. The acquired spectra were 
searched against a customized database, combining target HSA sequence with the yeast Uniprot database 
and common contaminants.35 The monoisotopic precursor mass tolerance was 10 ppm, and the 
monoisotopoic fragment mass tolerance was 0.02Da. Criteria of a minimum of 6 amino acids and 2 miss 
cleavages were used for search. Cysteine carbamidomethylation (+57.05130) was treated as a fixed 
modification, and all the other amino acids were treated as the dynamic modification (+416.13478) by the 
insertion of carbene species generated from probe 2. The reversed sequences of the original searching 
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database were used as the decoy database for FDR estimation. The strict FDR cutoff: 0.01 and Percolator 
were used to filter the false positives. All the HSA peptides identified with labelling (Supplemental 
Information: Table S4, Figures S4-S10) were further manual verified for accuracy. 
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